市場調査レポート
商品コード
1298659
肝疾患治療市場:世界の産業動向、シェア、規模、成長機会、2023-2028年予測Liver Disease Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
肝疾患治療市場:世界の産業動向、シェア、規模、成長機会、2023-2028年予測 |
出版日: 2023年06月14日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2~3営業日
|
世界の肝疾患治療市場規模は2022年に223億米ドルに達しました。今後、IMARC Groupは、2023年から2028年にかけて6.43%の成長率(CAGR)を示し、2028年には330億米ドルに達すると予測しています。
肝臓は、ビタミンや栄養素の貯蔵、血液中の有害物質の除去、体内の化学物質の適切なバランスの維持など、重要な機能を果たす人体の重要な臓器です。がん、肝炎、自己免疫疾患、遺伝性疾患などが一般的な肝臓の病気です。これらの病気は一般的に、感染症、遺伝、肥満、糖尿病、免疫系の異常によって引き起こされます。肝疾患の治療法として広く用いられているものには、ワクチン、化学療法、抗ウイルス薬、免疫グロブリン、コルチコステロイド、免疫抑制剤などがあります。肝疾患治療薬は、コレステロールやホルモンの排泄を助け、胆汁の産生を増加させ、酵素の活性化を促進します。
肝疾患を含む様々な慢性疾患に罹患しやすい老年人口が世界中で増加していることは、市場の成長を促進する主な要因の一つです。食事パターンの変化と座りがちなライフスタイルが市場成長を後押ししています。さらに、高コレステロール、肥満、高血圧、糖尿病による脂肪肝疾患の有病率の増加が、市場の成長を後押ししています。さらに、バイオ人工肝臓の市場開拓など、さまざまな技術の進歩が市場成長に弾みをつけています。これは再生肝細胞を利用して肝機能を代替するもので、急性肝不全患者に広く使用されています。これに伴い、安全で効果的であり、B型肝炎ウイルスの抑制を助け、肝硬変や肝細胞がんのリスク軽減に役立つ抗ウイルス薬の急速な採用が、市場成長にプラスの影響を与えています。これとは別に、研究開発(R&D)活動の増加、ヘルスケア産業の著しい成長、公衆衛生を促進するための様々な政府イニシアチブの実施は、市場に明るい見通しを生み出しています。
The global liver disease treatment market size reached US$ 22.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 33.0 Billion by 2028, exhibiting a growth rate (CAGR) of 6.43% during 2023-2028.
The liver is a vital organ of the human body that performs significant functions, such as storing vitamins and nutrients, removing harmful substances from the blood, and maintaining an adequate balance of chemicals in the body. Cancer, hepatitis, autoimmune diseases, and genetic disorders are some common liver diseases. These diseases are commonly caused by infections, genetics, obesity, diabetes, and immune system abnormalities. Some of the widely used therapeutic techniques for liver diseases include vaccines, chemotherapy, antiviral drugs, immunoglobulins, corticosteroids, and immunosuppressants. Liver disease treatment aids in the excretion of cholesterol and hormones, increases bile production and enzyme activation.
The rising geriatric population, which is suspetible to various chronic ailments, including liver disease, across the globe is one of the prime factors driving the growth of the market. The changing dietary patterns and sedentary lifestyles are boosting the market growth. Additionally, the increasing prevalence of fatty liver disease due to high cholesterol, obesity, hypertension (high blood pressure), and diabetes is favoring the market growth. Moreover, various technological advancements, such as the development of the bioartificial liver, are providing an impetus to the market growth. It utilizes regenerated liver cells to replace liver functions and is widely used for acute liver failure patients. In line with this, the rapid adoption of antiviral drugs as they are safe and effective, assist in suppressing the hepatitis B virus, and help in reducing the risk of developing cirrhosis and hepatocellular carcinoma, is positively impacting the market growth. Apart from this, increasing research and development (R&D) activities, significant growth in the healthcare industry, and the implementation of various government initiatives to promote public health are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global liver disease treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on treatment type, disease type and end user.
Antiviral Drugs
Immunosuppressants
Vaccines
Immunoglobulins
Corticosteroids
Targeted Therapy
Chemotherapy
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
Hospitals
Ambulatory Surgical Centers
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Viatris Inc.
Key Questions Answered in This Report
1. What was the size of the global liver disease treatment market in 2022?
2. What is the expected growth rate of the global liver disease treatment market during 2023-2028?
3. What are the key factors driving the global liver disease treatment market?
4. What has been the impact of COVID-19 on the global liver disease treatment market?
5. What is the breakup of the global liver disease treatment market based on the treatment type?
6. What is the breakup of the global liver disease treatment market based on the disease type?
7. What is the breakup of the global liver disease treatment market based on the end user?
8. What are the key regions in the global liver disease treatment market?
9. Who are the key players/companies in the global liver disease treatment market?